Preterm Birth Clinical Trial
— NORACTOfficial title:
Nordic Randomized Trial on Laparoscopic Versus Vaginal Cerclage
Every year 15 million babies are born prematurely, which can lead to death or life-long disabilities. It is often caused by a dysfunction of the uterine cervix, which constitutes the narrow channel between the vagina and womb. During pregnancy, this channel must remain closed until the beginning of term labor. A weak cervix may not withstand the weight of the fetus, the amniotic fluid and the placenta and the cervical canal will open and cause late miscarriage or preterm delivery. To prevent this, a band (cerclage) can be applied around the cervix either vaginally or laparoscopically prior to a new pregnancy. To evaluate which treatment is best for most women, we will randomize (allocate by chance) women at risk for preterm birth, to either vaginal cerclage or laparoscopic cerclage in the Nordic countries and England
Status | Recruiting |
Enrollment | 188 |
Est. completion date | March 2028 |
Est. primary completion date | December 2027 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Women in whom the clinician has equipoise as to whether an elective vaginal or abdominal cerclage will be the best intervention to prevent preterm birth. - Not yet pregnant or <10 weeks' pregnant. Exclusion Criteria: - Any circumstance under which the clinician is not willing to randomize is an exclusion criterion. - Any condition or circumstance under which laparoscopic or vaginal cerclage surgery is contraindicated (i.e. on-going pregnancy of more than 10+0 gestational weeks). - Language difficulties. |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital | Aarhus N | |
Denmark | Rigshospitalet | København |
Lead Sponsor | Collaborator |
---|---|
Aarhus University Hospital | Hvidovre University Hospital, Odense University Hospital, Oslo University Hospital, Rigshospitalet, Denmark, Viborg Regional Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Delivery <32+0 weeks of gestation. | In the first subsequent viable pregnancy beyond 14+0 weeks of gestation. First prioritized primary outcome. | At birth. | |
Primary | Baby death. | Loss of a viable pregnancy beyond 14+0 weeks of gestation, miscarriage, stillbirth or death of a live born infant. Second prioritized primary outcome. | From birth - four weeks after due date. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | |
Secondary | Maternal mortality - surgery related. | Death. | 30 days after insertion of laparoscopic or vaginal cerclage. | |
Secondary | Maternal mortality. | Death. | From time of randomisation - 42 days after delivery. | |
Secondary | Maternal morbidity - surgery related. | Admission to ICU or a unit that provides 24-h medical supervision and is able to provide mechanical ventilation or continuous vasoactive drug support. | 30 days after insertion of laparoscopic or vaginal cerclage. | |
Secondary | Maternal morbidity | Admission to ICU or a unit that provides 24-h medical supervision and is able to provide mechanical ventilation or continuous vasoactive drug support. | From time of randomisation - 42 days after delivery. | |
Secondary | Harm to participant - surgery related. | One or more of the following: Damage to internal organs, need for re-operation, thromboembolic events (defined as deep vein thrombosis, pulmonary embolism or stroke), maternal cardiopulmonary arrest. | 30 days after insertion of laparoscopic or vaginal cerclage. | |
Secondary | Harm to participant | One or more of the following: Damage to internal organs, thromboembolic events (defined as deep vein thrombosis, pulmonary embolism or stroke), maternal cardiopulmonary arrest. | From time of cerclage procedure - 42 days after delivery. | |
Secondary | Bleeding - surgery related. | Blood loss > 500 ml. | 30 days after insertion of laparoscopic or vaginal cerclage. | |
Secondary | Bleeding - pregnancy related. | Blood loss > 1000 ml. | From time of cerclage procedure - 42 days after delivery. | |
Secondary | Maternal infection - surgery related. | Leading to antibiotic treatment, but not ICU. | 30 days after insertion of laparoscopic or vaginal cerclage. | |
Secondary | Maternal infection - pregnancy related. | Leading to antibiotic treatment, but not ICU | From time of cerclage procedure - 42 days after delivery | |
Secondary | Maternal serious infection - pregnancy related. | Admission to ICU due to serious infection. | From time of cerclage procedure - 42 days after delivery. | |
Secondary | Maternal serious infection - surgery related. | Admission to ICU due to serious infection. | 30 days after insertion of laparoscopic or vaginal cerclage. | |
Secondary | PPROM. | Preterm prelabour rupture of membranes, in the first subsequent viable pregnancy beyond 14 weeks of gestation. | At birth. | |
Secondary | Threatened preterm labour. | Threatened preterm labour requiring admission and intervention, in the first subsequent viable pregnancy beyond 14 weeks of gestation. | At birth. | |
Secondary | Onset of labour. | Spontaneous labor contractions, PROM, induction of labor, c-section. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | At birth. | |
Secondary | Mode of birth. | Unassisted vaginal, assisted vaginal (ventouse or forceps), caesarean section (planned, non-planned). In the first subsequent viable pregnancy beyond 14 weeks of gestation. | At birth. | |
Secondary | Modified neonatal mortality. | Death of a liveborn child > 22+0 weeks of gestation. | From birth - four weeks after due date. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | |
Secondary | Neonatal mortality. | Death in the 1st 28 days of life > 22+0 weeks of gestation. | From birth - 28 days post delivery. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | |
Secondary | Fetal loss. | Composite of late miscarriage and stillbirth, in the first subsequent viable pregnancy beyond 14 weeks of gestation. | At due date. | |
Secondary | Late miscarriage. | Loss of viable pregnancy between gestational age 14+0-21+6, in the first subsequent viable pregnancy beyond 14 weeks of gestation. | At due date. | |
Secondary | Gestational age at birth. | Gestational age at birth, weeks and days, in the first subsequent viable pregnancy beyond 14 weeks of gestation. | At birth. | |
Secondary | Delivery < 28 weeks. | Birth before gestational age 28+0, in the first subsequent viable pregnancy beyond 14 weeks of gestation. | At birth. | |
Secondary | Delivery < 34 weeks. | Birth before gestational age 34+0, in the first subsequent viable pregnancy beyond 14 weeks of gestation. | At birth. | |
Secondary | Delivery < 37 weeks. | Birth before gestational age 37+0, in the first subsequent viable pregnancy beyond 14 weeks of gestation. | At birth. | |
Secondary | Birthweight. | Grams. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | At birth. | |
Secondary | Neonatal admission. | Number of consecutive days in hospital within 28 days from time of delivery. In the first subsequent viable pregnancy beyond 14 weeks of gestation.
Any admission counts (SCBU, maternity ward, NICU) |
From birth - four weeks after due date. | |
Secondary | CNS morbidity. | Intraventricular Hemorrhage Grade III and IV and/or Periventricular leukomalacia. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | From birth - four weeks after due date. | |
Secondary | Ocular morbidity. | Retinopathy requiring treatment. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | From birth - four weeks after due date. | |
Secondary | Gastrointestinal morbidity. | Necrotizing Enterocolitis (NEC) and/or SIP (Spontaneous intestinal perforation), requiring surgery. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | From birth - four weeks after due date. | |
Secondary | Respiratory support. | Mechanical ventilation or non-invasive ventilation. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | From birth - four weeks after due date. | |
Secondary | Respiratory distress syndrome (RDS). | Need for surfactant treatment. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | First two days of life. | |
Secondary | Early onset neonatal infection. | >5 days of i.v. antibiotics, where the treatment commences within the first week of life. In the first subsequent viable pregnancy beyond 14 weeks of gestation. | From birth - four weeks after due date. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Completed |
NCT05502510 -
Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
|
||
Not yet recruiting |
NCT03418311 -
Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome
|
N/A | |
Not yet recruiting |
NCT03418012 -
Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB
|
N/A | |
Completed |
NCT02993744 -
Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone
|
N/A | |
Active, not recruiting |
NCT02673216 -
Infection and Adverse Pregnancy Outcome
|
||
Completed |
NCT01683565 -
Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood
|
Phase 4 | |
Completed |
NCT01460576 -
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
|
N/A | |
Completed |
NCT01412931 -
Protein and Ultrasound Indicators of Preterm Birth
|
N/A | |
Completed |
NCT02606058 -
The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?
|
N/A | |
Terminated |
NCT03715530 -
Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women
|
N/A | |
Completed |
NCT00422526 -
Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial
|
Phase 3 | |
Enrolling by invitation |
NCT04251260 -
Effectiveness of Positioning in Preterm Neonates
|
N/A | |
Completed |
NCT03668860 -
India Dexamethasone and Betamethasone
|
Phase 1 | |
Recruiting |
NCT03638037 -
Correlation Between Maternal Vitamin D Level And Preterm Birth
|
||
Completed |
NCT02225353 -
Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
|
Phase 2 | |
Recruiting |
NCT03992534 -
The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth
|
Phase 1 | |
Completed |
NCT03144141 -
Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery
|
N/A | |
Completed |
NCT05210985 -
Examination of the Relationship Between Home Affordances With Development
|
||
Completed |
NCT04811742 -
Effect of Immersion Bathing and Showering Applications on Comfort Level and Physiological Parameters of Newborn
|
N/A |